Archive · 29 Jul 2025
Piramal Pharma Q1 Net Loss at ₹82 Crore
Piramal Pharma, a drug company, announced a loss of ₹82 crore for the first three months of 2025.
This is still a loss, but a smaller one than the previous year.
The company's income slightly decreased overall.
However, the contract development and manufacturing (CDMO) business performed well.
Piramal Pharma is aiming to significantly increase its revenue by 2030.
Piramal Pharma reported a consolidated net loss of ₹82 crore in Q1 2025.
Revenue from operations declined to ₹1,934 crore in Q1.
The company had a loss of ₹89 crore in the same quarter last year.
CDMO business showed mid-teen revenue growth, excluding destocking impact.
Piramal aims to reach $2 billion revenue by FY2030.
- Who
- Piramal Pharma
- What
- Piramal Pharma reported a net loss of ₹82 crore
- When
- During the first quarter ended June 30, 2025
- Where
- Mumbai
- Why
- Due to operational factors and market conditions.
- Net Loss
- ₹82 crore
- Revenue (Q1 2025)
- ₹1,934 crore
- Net Loss (Q1 2024)
- ₹89 crore
- Share Price (at close)
- ₹202.20
- Revenue Goal (FY2030)
- $2 billion
Sources
Ajanta Pharma Q1 net profit up 4% to ₹255 crore on strong revenue growth, margin slips slightly
Ajanta Pharma net profit rises 4% to ₹255 cr in June qtr
Ajanta Pharma Q1 Profit Rises 4% To ₹255 Crore On Strong Growth In Branded Generic Sales
Torrent Pharma’s net profits grow 20% to ₹548 cr during Q1, FY26
Piramal Pharma Q1 net loss at ₹82 crore